Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia

Frontiers in Genetics

Volumn 3, Issue NOV, 2012, Pages

  Gervasini, Guillermo ^a   Vagace, Jose M ^b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Genetic polymorphisms; Pharmacogenetics; Toxicity

Indexed keywords

EID: 84876097549     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00249     Document Type: Review

References (113)

1. Adam de Beaumais, T., and Jacqz-Aigrain, E. (2012). Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Fur. J. Clin. Pharmacol 68, 1233-1242.
2. Agundez, J. A. (2004). Cytochrome P450 gene polymorphism and cancer. Curr. DrugMetab. 5, 211-224.
3. Agundez, J. A., Del Barrio, J., Padro, T., Stephens, C, Farre, M., Andrade, R. J., etal. (2012). Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish society of clinical pharmacology. Front. Pharmacol. 3, 1-6.
4. Allan, D. S., Kovacs, M. J., and Clark, W. F. (2001). Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immuno-suppressive therapy. Haematologica 86,844-850.
5. Ban, H., Andoh, A., Imaeda, H., Kobori, A., Bamba, S., Tsujikawa, T., etal. (2010). The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.j Gastroenterol 45,1014-1021.
6. Banklau, C, Jindadamrongwech, S., Sawangpanich, R., Apibal, S., Hongeng, S., Paisooksantivatana, K., et al. (2010). Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol. Oncol. Stem Cell Ther. 3, 103-108.
7. Bhatla, D., Gerbing, R. B., Alonzo, T. A., Conner, H., Ross, J. A., Meshinchi, S., etal. (2009). Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144, 388-394.
8. Bleibel, W. K., Duan, S., Huang, R. S., Kistner, E. O., Shukla, S. J., Wu, X., etal. (2009). Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum. Genet. 125, 173-180.
9. Bolton, A. E., Peng, B., Hubert, M., Krebs-Brown, A., Capdeville, R., Keller, U., etal. (2004). Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53, 102-106.
10. Bray, J., Sludden, J., Griffin, M. J., Cole, M., Verrill, M., Jamieson, D., etal. (2010). Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer 102, 1003-1009.
11. Campalani, E., Arenas, M., Marinaki, A. M., Lewis, C. M., Barker, J. N., and Smith, C. H. (2007). Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.j Invest. Dermatol. 127, 1860-1867.
12. Chabner, B. A., Allegra, C. J., Curt, G. A., Clendeninn, N. J., Baram, J., Koizumi, S., etal. (1985). Polyglutamation of methotrexate. Is methotrexate a prodrug?j Clin. Invest. 76, 907-912.
13. Chatzidakis, K., Goulas, A., Athanassiadou-Piperopoulou, E, Fidani, L., Koliouskas, D., and Mirtsou, V. (2006). Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr. Blood Cancer 47, 147-151.
14. Chen, S. H., Pei, D., Yang, W., Cheng, C, Jeha, S., Cox, N. J., etal. (2010). Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity Clin. Pharmacol. Ther. 88, 191-196.
15. Chen, S.H., Yang, W., Fan, Y.,Stocco, G., Crews, K. R., Yang, J. J., etal. (2011). A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity Leukemia 25, 66-74.
16. Cho, H. J., Eom, H. S., Kim, H. J., Kim, I. S., Lee, G. W., and Kong, S. Y. (2010). Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet. Cytogenet. 198,40-46.
17. Ciccolini, J., Evrard, A., M'Batchi, L., Pourroy, B., Mercier, C, Iliadis, A., etal. (2012). CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 13,393-397.
18. Cortijo-Cascajares, S., Jimenez-Cerezo, M. J., and Herreros De Tejada, A. (2012). Review of hypersensitivity reactions to antineoplastic agents. Farm. Hosp. 36, 148-158.
19. Cotte, S., Von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U. K., etal. (2009). ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132, 2517-2530.
20. Cox, P. J. (1979). Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem. Pharmacol. 28, 2045-2049.
21. D'Angelo, V., Ramaglia, M., Iannotta, A., Crisci, S., Indolfi, P., Francese, M., etal. (2011). Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother. Pharmacol. 68, 1339-1346.
22. Dennison, J. B., Kulanthaivel, P., Barbuch, R. J., Renbarger, J. L, Ehlhardt, W. J., and Hall, S. D. (2006). Selective metabolism of vincristine in vitro byCYP3A5. DrugMetab. Dispos. 34, 1317-1327.
23. Dirven, H. A., Venekamp, J. C, Van Ommen, B., and Van Bladeren, P. J. (1994). The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 3 IP nuclear magnetic resonance spectroscopy. Chem. Biol. Interact. 93,185-196.
24. Drocourt, L., Ourlin, J. C, Pascussi, J. M., Maurel, P., and Vilarem, M. J. (2002). Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.j Biol. Chem. 277,25125-25132.
25. Dulucq, S., and Krajinovic, M. (2010). The pharmacogenetics of imanitib. Genome Med. 2, 85.
26. Ekhart, C, Rodenhuis, S., Smits, P. H., Beijnen, J. H., and Huitema, A. D.(2008). Relations between poly morphisms in drug-metabolising enzymes and toxicity of chemother apy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet. Genomics 18, 1009-1015.
27. Erdilyi, D. J., Kamory, E., Csokay, B., Andrikovics, H., Tordai, A., Kiss, C, etal. (2008). Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anti-cancer chemotherapy. Pharmacogenomicsj. 8,321-327.
28. FDA (2011). Table of Pharmacogenomic Biomarkers in Drug Lables [Online]. Available: http://www. fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ ucmO83378.htm [Accessed].
29. Flores-Calderon, J., Exiga-Gonzalez, E., Moran-Villota, S., Martin-Trejo, J., and Yamamoto-Nagano, A. (2009). Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase.j Pediatr. Hematol Oncol 31, 790-793.
30. Galivan, J. (1980). Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17, 105-110.
31. Gardner, E. R., Burger, H., Van Schaik, R. H., Van Oosterom, A. T., De Bruijn, E.A., Guetens, G., et al. (2006). Asso ciation of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol Ther. 80,192-201.
32. Gervasini, G. (2009). Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr. Drug Metab. 10, 547-566.
33. Gilladoga, A. C, Manuel, C, Tan, C. T., Wollner, N., Sternberg, S. S., and Murphy, M. L. (1976). The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37, 1070-1078.
34. Gonzalez-Covarrubias, V, Ghosh, D., Lakhman, S. S., Pendyala, L., and Blanco, J. G. (2007). A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab. Dispos. 35, 973-980.
35. Groenen, P. M. (2011). Four decades of modern pharmacogenomics: from promise to clinical utility. World PGX Summit 2011, Boston, USA, 26-27 April, 2011. Pharmacogenomics 12, 1249-1252.
36. Gugliotta, L., Mazzucconi, M. G., Leone, G., Mattioli-Belmonte, M., Defazio, D., Annino, L, etal. (1992). Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur. J. Haematol 49, 63-66.
37. Guillem, V M., Collado, M., Terol, M. J., Calasanz, M. J., Esteve, J., Gonzalez, M., et al. (2007). Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 21, 1413-1422.
38. Gurney, H., Wong, M., Balleine, R. L., Rivory, L. P., Mclachlan, A. J., Hoskins, J. M., etal. (2007). Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol Ther. 82, 33-40.
39. Hartford, C. M., Duan, S., Delaney, S. M., Mi, S., Kistner, E. O., Lamba, J. K., etal. (2009). Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113, 2145-2153.
40. Hartman, A., Van Schaik, R. H., Van Der Heiden, I. P., Broekhuis, M. J., Meier, M., Den Boer, M. L., et al. (2010). Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk. Res. 34, 154-159.
41. Hasan, S., Dinh, K., Lombardo, E, and Kark, J. (2004). Doxorubicin cardiotoxicity in African Americans.j Nail. Med. Assoc. 96, 196-199.
42. Hawwa, A. E, Millership, J. S., Collier, P. S., Vandenbroeck, K., McCarthy, A., Dempsey, S., etal. (2008). Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66, 517-528.
43. Hayes, J. D., and Pulford, D. J. (1995). The glutathione S-transferase super-gene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30,445-600.
44. Heller, T., Oellerich, M., Armstrong, V W, and Von Ahsen, N. (2004). Rapid detection of ITPA 94C>A and IVS2+ 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2+21A>C polymorphism on splicing efficiency. Clin. Chem. 50, 2182-2184.
45. Huang, L., Tissing, W. J., De Jonge, R., Van Zelst, B. D., and Pieters, R. (2008). Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 22, 1798-1800.
46. Huang, R. S., Duan, S., Bleibel, W K., Kistner, E. O., Zhang, W., Clark, T. A., etal. (2007). A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Nail. Acad. Sci. U.S.A. 104, 9758-9763.
47. Huang, Z., Roy, P., and Waxman, D. J. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59,961-972.
48. Imanishi, H., Okamura, N., Yagi, M., Noro, Y, Moriya, Y, Nakamura, T., etal. (2007). Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.j Hum. Genet. 52, 166-171.
49. Jamieson, D., and Boddy, A. V (2010). Pharmacogenetics of genes across the doxorubicin pathway. Expert Opin. Drug Metab. Toxicol. 7, 1201-1210.
50. Judson, I., Ma, P., Peng, B., Verweij, J., Racine, A., Di Paola, E. D., etal. (2005). Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55, 379-386.
51. Kantar, M., Kosova, B., Cetingul, N., Gumus, S., Toroslu, E., Zafer, N., etal. (2009). Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk. Lymphoma 50, 912-917.
52. Karas-Kuzelicki, N., Jazbec, J., Milek, M., and Mlinaric-Rascan, I. (2009). Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23, 971-974.
53. Kim, I. S., Kim, H. G., Kim, D. C, Eom, H. S., Kong, S. Y, Shin, H. J., etal. (2008). ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/ doxorubicin/vincristine/prednisone chemotherapy. Cancer Sci. 99, 2496-2501.
54. Kirch, H. C, Schroder, J., Hoppe, H., Esche, H., Seeber, S., and Schutte, J. (1998). Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp. Hematol. 26, 421-425.
55. Kirchheiner, J., Klein, C, Meineke, I., Sasse, J., Zanger, U. M., Murdter, T. E., etal. (2003). Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13, 619-626.
56. Kishi, S., Cheng, C, French, D., Pei, D., Das, S., Cook, E. H., etal. (2007). Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109, 4151-4157.
57. Kishi, S., Griener, J., Cheng, C, Das, S., Cook, E. H., Pei, D., etal. (2003). Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.j Clin. Oncol. 21, 3084-3091.
58. Kishi, S., Yang, W, Boureau, B., Morand, S., Das, S., Chen, P., etal. (2004). Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103, 67-72.
59. Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E., and Sugiyama, Y (2010). Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcbl) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.j Pharmacol. Exp. Ther. 333, 788-796.
60. Kong, J. H., Mun, Y. C, Kim, S., Choi, H. S., Kim, Y K., Kim, H. J., etal. (2012). Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. Int. J. Hematol. 96, 327-333.
61. Krajinovic, M., Robaey, P., Chiasson, S., Lemieux-Blanchard, E., Rouillard, M., Primeau, M., etal. (2005). Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 6, 293-302.
62. Lal, S., Mahajan, A., Chen, W. N., and ChowbayB. (2010). Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr. Drug Metab. 11, 115-128.
63. Lal, S., Wong, Z. W., Jada, S. R., Xiang, X., Chen Shu, X., Ang, P. C, etal. (2007). Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8, 567-575.
64. Lal, S., Wong, Z. W., Sandanaraj, E., Xiang, X., Ang, P. C, Lee, E. J., etal. (2008). Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 99, 816-823.
65. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., etal. (2001). Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11,399-415.
66. Laningham, F. H., Kun, L. E., Reddick, W. E., Ogg, R. J., Morris, E. B., and Pui, C. H. (2007). Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49, 873-888.
67. Lennard, L., and Lilleyman, J. S. (1996). Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther. Drug Monit. 18, 328-334.
68. Low, S. K., Kiyotani, K., Mushiroda, T., Daigo, Y., Nakamura, Y., and Zembutsu, H. (2009). Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.j Hum. Genet. 54,564-571.
69. Ludeman, S. M. (1999). The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 5, 627-643.
70. Mahadeo, K. M., Dhall, G., Panigrahy, A., Lastra, C, and Ettinger, L. J. (2010). Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr. Hematol. Oncol 27,46-52.
71. McLeod, H. L., Coulthard, S., Thomas, A. E., Pritchard, S. C, King, D. J., Richards, S. M., etal. (1999). Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 105, 696-700.
72. McLeod, H. L, Krynetski, E. Y, Relling, M. V., and Evans, W. E. (2000). Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567-572.
73. Moore, A., and Pinkerton, R. (2009). Vincristine: can its therapeutic index be enhanced? Pediatr. Blood Cancer 53,1180-1187.
74. Moscow, J. A., Gong, M., He, R., Sgagias, M. K., Dixon, K. H., Anzick, S. L., etal. (1995). Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 55, 3790-3794.
75. Ngamjanyaporn, P., Thakkinstian, A., Verasertniyom, O., Chatchaipun, P., Vanichapuntu, M., Nantiruj, K., etal. (2011). Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatol. Int. 31,1215-1218.
76. Ongaro, A., De Mattei, M., Delia Porta, M. G., Rigolin, G., Ambrosio, C, Di Raimondo, F., etal. (2009). Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 94, 1391-1398.
77. Pacheco, R., Gallart, T., Lluis, C, and Franco, R. (2007). Role of glutamate on T-cell mediated immunity.j Neuroimmunol 185, 9-19.
78. Palmieri, O., Latiano, A., Bossa, E, Vecchi, M., D'Inca, R., Guagnozzi, D., etal. (2007). Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment. Pharmacol. Ther. 26, 737-745.
79. Parekh, H. K., and Sladek, N. E. (1993). NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem. Pharmacol. 46, 1043-1052.
80. Peng, B., Lloyd, P., and Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44, 879-894.
81. Petain, A., Kattygnarath, D., Azard, J., Chatelut, E., Delbaldo, C, Geoerger, B., etal. (2008). Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res. 14, 7102-7109.
82. Plasschaert, S. L., Groninger, E., Boezen, M., Kema, I., De Vries, E. G., Uges, D., etal. (2004). Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 76, 220-229.
83. Pui, C. H., Relling, M. V., and Downing, J. R. (2004). Acute lymphoblastic leukemia. N. Engl.j. Med. 350,1535-1548.
84. Ranganathan, P., Culverhouse, R., Marsh, S., Mody, A., Scott-Horton, T. J., Brasington, R., etal. (2008). Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.j Rheumatol. 35, 572-579.
85. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., etal. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89,387-391.
86. Relling, M. V., Nemec, J., Schuetz, E. G., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R. (1994). O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45, 352-358.
87. Renbarger, J. L., Mccammack, K. C, Rouse, C. E., and Hall, S. D. (2008). Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr. Blood Cancer 50, 769-771.
88. Restrepo, J. G., Martinez, C, Garcia-Agundez, A., Gaviria, E., Laguna, J. J., Garcia-Martin, E., etal. (2011). Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet. Genomics 21,773-778.
89. Rocha, V., Porcher, R., Fernandes, J. E, Filion, A., Bittencourt, H., Silva, W. Jr., etal. (2009). Association of drug metabolism gene polymorphisms with toxicities, graft -versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23, 545-556.
90. Rousseau, J., Gagne, V., Labuda, M., Beaubois, C, Sinnett, D., Laverdiere, C, etal. (2011). ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 118, 5883-5890.
91. Shimasaki, N., Mori, T., Samejima, H., Sato, R., Shimada, H., Yahagi, N., etal. (2006). Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.j Pediatr. Hematol. Oncol. 28, 64-68.
92. Song, S., Suzuki, H., Kawai, R., and Sugiyama, Y. (1999). Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab. Dispos. 27, 689-694.
93. Stanulla, M., Schaeffeler, E., Flohr, T., Cario, G., Schrauder, A., Zimmermann, M., etal. (2005). Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293, 1485-1489.
94. Stocco, G., Cheok, M. H., Crews, K. R., Dervieux, T., French, D., Pei, D., etal. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172.
95. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., etal. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. 159, 2542-2550.
96. Strunk, T., Gottschalk, S., Goepel, W., Bucsky, P., and Schultz, C. (2003). Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Med. Pediatr. Oncol 40,48-50.
97. Su, H. I., Sammel, M. D., Velders, L., Horn, M., Stankiewicz, C, Matro, J., etal. (2010). Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril. 94, 645-654.
98. Szeto, D. W, Cheng, Y. C, Rosowsky, A., Yu, C. S., Modest, E. J., Piper, J. R., etal. (1979). Human thymidylate synthetase - III. Effects of methotrexate and folate analogs. Biochem. Pharmacol 28, 2633-2637.
99. Takada, K., Arefayene, M., Desta, Z., Yarboro, C. H., Boumpas, D. T., Balow, J. E., et al. (2004). Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50, 2202-2210.
100. Vagace, J. M., Caceres-Marzal, C, Jimenez, M., Casado, M. S., De Murillo, S. G., and Gervasini, G. (2011). Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related tofolate homeostasis. Am. J. Hematol 86,98-101.
101. Vagace, J. M., De La Maya, M. D., Caceres-Marzal, C, Gonzalez De Murillo, S., and Gervasini, G. (2012). Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma. Crit. Rev. Oncol Hematol. 84, 274-286.
102. Vagace, J.M., and Gervasini, G. (2011). "Chemotherapy toxicity in patients with acute leukemia," in Acute Leukemia: The Scientist's Perspective and Challenge, ed. M. Antica (Rijeka, Croatia: INTECH), 391-414.
103. Varatharajan, S., Abraham, A., Zhang, W., Shaji, R. V., Ahmed, R., Abraham, A., etal. (2012). Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur. J. Clin. Pharmacol, doi: 10.1007/s00228-012-1291-9 [Epub ahead of print].
104. Vivona, D., Bueno, C. T., Lima, L. T., Hirata, R. D., Hirata, M. H., Luchessi, A. D., etal. (2012). ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol. Dis. 48, 132-136.
105. Wan Rosalina, W. R., Teh, L. K., Mohamad, N., Nasir, A., Yusoff, R., Baba, A. A., etal. (2011). Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.j Clin. Pharm. Ther. 37,237-241.
106. Watanabe, Y., Nakajima, M., Ohashi, N., Kume, T., and Yokoi, T. (2003). Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab. Dispos. 31, 589-595.
107. Weinshilboum, R. (2001). Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab. Dispos. 29,601-605.
108. Weisman, M. H., Furst, D. E., Park, G. S., Kremer, J. M., Smith, K. M., Wallace, D. J., etal. (2006). Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 54, 607-612.
109. Wessels, J. A., Van Der Kooij, S. M., Le Cessie, S., Kievit, W, Barerra, P., Allaart, C. E, etal. (2007). A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 1765-1775.
110. Xu, P. P., Chen, B. A., Feng, J. E, Cheng, L., Xia, G. H., Li, Y. E, etal. (2012). Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin. Med. J. (Engl.) 125, 2137-2143.
111. Yang, L., Hu, X., and Xu, L. (2012). Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 33, 1445-1454.
112. Zhong, S., Huang, M., Yang, X., Liang, L., Wang, Y, Romkes, M., etal. (2006). Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br. J. Clin. Pharmacol. 62, 457-472.
113. Zielinska, E., Zubowska, M., and Misiura, K. (2005). Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. j Pediatr. Hematol. Oncol. 27, 582-589.